Why ImmunityBio Stock Is Skyrocketing Again Today [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
It also highlighted initial success in treating patients with Non-Hodgkin lymphoma with one of its next-gen therapies. These developments follow four other significant business updates from earlier this week that have helped the stock double in five days. 10 stocks we like better than ImmunityBio › Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX) , spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible slate of good news. This morning, the company announced two bits of great news. First, enrollment for the company's Anktiva therapy exceeded expectations in a trial when treating non-muscle-invasive bladder cancer. This development means ImmunityBio could submit a biologics licensing agreement to the FDA by year's end. Second, another clinical trial showed that the company's CAR-NK therapy demonstrated 100% disease control in its first four patients with Non-Hodgkin lymphoma. This upda
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits? [Yahoo! Finance]Yahoo! Finance
- Ford & BYD reportedly in talks to partner, PNC rises on earnings [Yahoo! Finance Canada]Yahoo! Finance Canada
- ImmunityBio Says Potential Lymphoma Therapy Extends Complete Response to 15 Months [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 1/16/26 - Form 144
- 1/15/26 - Form 8-K
- 1/14/26 - Form 8-K
- IBRX's page on the SEC website